Alice M Shaw from 1504 S Lodge Dr, Sarasota, FL 34239, age 74, Phone: (941) 951-2397

Professional Records

License Records

Alice Mary Shaw

License #:

49257 - Expired

Category:

Nursing Support

Issued Date:

Dec 27, 2002

Effective Date:

Jan 6, 2009

Expiration Date:

Dec 27, 2008

Type:

Medication Aide

Medicine Doctors

Alice T. Shaw

View page

Specialties:

Medical Oncology, Internal Medicine

Work:

Massachusetts General Hospital Cancer Center
32 Fruit St FL 7-9, Boston, MA 02114
(617) 724-4000 (phone), (617) 726-1949 (fax)

Education:

Medical School
Harvard Medical School
Graduated: 1999

Procedures:

Vaccine Administration

Conditions:

Anxiety Phobic Disorders
Chronic Renal Disease
Diabetes Mellitus (DM)
Disorders of Lipoid Metabolism
Malignant Neoplasm of Female Breast

Languages:

English
Spanish

Description:

Dr. Shaw graduated from the Harvard Medical School in 1999. She works in Boston, MA and specializes in Medical Oncology and Internal Medicine. Dr. Shaw is affiliated with Massachusetts General Hospital.

Lawyers & Attorneys

Alice Shaw - Lawyer

View page

ISLN:

901105972

Admitted:

1991

University:

Wofford College, B.A., 1987

Law School:

University of South Carolina, J.D., 1991

Resumes

Alice Shaw

View page

Location:

United States

Alice Shaw

View page

Location:

United States

Alice Shaw

View page

Location:

United States

Alice Shaw

View page

Location:

United States

Alice Shaw

View page

Location:

United States

Alice Shaw

View page

Location:

United States

Business Records

Name / Title

Company / Classification

Phones & Addresses

Alice M Shaw
Manager

JUNIPER WELL RANCH OF FLORIDA, LLC
General Animal Farm

10080 W Tough Country Trl, Skull Valley, AZ 86338
1504 Ldg Dr S, Sarasota, FL 34239

Alice Carol Shaw

SHAW & SON'S PRECISION CONTRACTING COMPANY, INC

Alice M. Shaw
Director

Shaw Stables, Inc
Business Services at Non-Commercial Site

1504 S Ldg Dr, Sarasota, FL 34239

Alice M. Shaw

Mayo Investments of Sarasota, Ltd

1504 S Ldg Dr, Sarasota, FL 34239

News

Immune therapy scores big win against lung cancer in study

View page

That's a big difference for such an advanced cancer, said Dr. Alice Shaw, a Massachusetts General Hospital lung cancer expert and one of the conference leaders. "This is really a pivotal study ... a new standard of care," said Shaw, who has no ties to the drugmakers.

Date

Apr 16, 2018

Category:

Health

Source:

Google

Roche's Alecensa trounces Pfizer's Xalkori in head-to-head ALK matchup—again

View page

Nobody imagined it would be possible to delay advanced lung cancer progression by this much. Most targeted therapies for lung cancer are associated with a median progression-free survival of roughly 12 months, lead study investigator Alice Shaw said in a statement.

Date

Jun 05, 2017

Category:

Health

Source:

Google

Norovirus outbreak suspected in numerous Santa Barbara County schools

View page

Schools in the Orcutt School District, which include Alice Shaw, Joe Nightingale, Patterson Road, Pine Grove and Ralph Dunlap schools, as well as ManzanitaCharter School on Vandenberg Air Force Base, are reporting numerous cases of gastrointestinal symptoms consistent with the norovirus, according

Date

May 26, 2017

Category:

Health

Source:

Google

Pfizer (PFE) Announces XALKORI Approved by FDA for Treatment of Patients with ROS1-Positive Metastatic NSCLC

View page

proval of crizotinib for metastatic ROS1-positive non-small cell lung cancer represents another significant step forward in biomarker-driven cancer care, said Dr. Alice Shaw, Associate Professor of Medicine at Massachusetts General Hospital and Harvard Medical School, and principal study investigator. As

Date

Mar 11, 2016

Category:

Health

Source:

Google

3 Pharmaceutical Giants on the Road to Curing Cancer

View page

cases of non-small cell lung cancer, have an abnormality to the ROS1 gene, according to the pharma giant Pfizer. The drug was also effective for approximately 18 months in patients, longer than the average eight to 12 months seen for some other targeted patients, said Alice Shaw, a lead study author.

Date

Sep 29, 2014

Source:

Google

Pfizer drug Xalkori effective against rare lung cancer in clinical trial

View page

"This is the first definitive study to establish crizotinib's activity in a large group of patients with ROS1-positive lung cancer and confirms that ROS1 is a bona fide therapeutic target in those patients," said Dr. Alice Shaw from the Massachusetts General Hospital Cancer Center in Boston.

Date

Sep 29, 2014

Category:

Health

Source:

Google

Positive Results Reported for Pfizer Drug against Rare Lung Cancer

View page

According to Dr. Alice Shaw from Massachusetts General Hospital Cancer Center in Boston, and also the lead investigator, this is the first detailed study to determine the effectiveness of crizotinib in a large group of patients. The study also confirms that ROS1 is a bona fide therapeutic target in

Date

Sep 29, 2014

Category:

Health

Source:

Google

Lung Cancer Treatment: Pfizer drug Xalkori effective in rare Pulmonary Cancer

View page

Alice Shaw, the studys lead investigator from the Massachusetts General Hospital Cancer Center in Boston, said in a statement, This is the first definitive study to establish crizotinibs activity in a large group of patients with ROS1-positive lung cancer and confirms that ROS1 is a bona fide th

Date

Sep 28, 2014

Category:

Health

Source:

Google

Videos & Images